As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
15 Analysts have issued a Aquestive Therapeutics, Inc. forecast:
15 Analysts have issued a Aquestive Therapeutics, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 44 44 |
24%
24%
|
|
Gross Profit | 27 27 |
33%
33%
|
|
EBITDA | -52 -52 |
270%
270%
|
EBIT (Operating Income) EBIT | -53 -53 |
246%
246%
|
Net Profit | -65 -65 |
153%
153%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
Head office | United States |
CEO | Daniel Barber |
Employees | 142 |
Founded | 2004 |
Website | aquestive.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.